Literature DB >> 8027926

Comparative study of buccoadhesive formulations and sublingual capsules of nifedipine.

T Save1, M U Shah, A R Ghamande, P Venkitachalam.   

Abstract

The pharmacodynamics of nifedipine administered via the oral mucosa was investigated in hypertensive patients. The effect of two buccoadhesive formulations, tablets and films, was compared with the commercially available sublingual capsule in a complete cross-over study in six patients. All three formulations elicited onset of action 10 min after administration. The sublingual capsule and the buccoadhesive film revealed peak response at 30 min. The buccoadhesive tablet, however, exhibited a delayed peak response at 45 min. Analysis of variance indicated that, although time-dependent differences in the formulations were suggested, there was no significant difference in the overall effect produced by the three formulations. The results of the study suggest that the buccoadhesive formulations of nifedipine were comparable in performance with the sublingual capsule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027926     DOI: 10.1111/j.2042-7158.1994.tb03776.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Preparation and characterization of nicotine-magnesium aluminum silicate complex-loaded sodium alginate matrix tablets for buccal delivery.

Authors:  Sopaphan Kanjanabat; Thaned Pongjanyakul
Journal:  AAPS PharmSciTech       Date:  2011-05-19       Impact factor: 3.246

2.  Design and in vitro/in vivo evaluation of novel mucoadhesive buccal discs of an antifungal drug: relationship between swelling, erosion, and drug release.

Authors:  Soad A Yehia; Omaima N El-Gazayerly; Emad B Basalious
Journal:  AAPS PharmSciTech       Date:  2008-12-11       Impact factor: 3.246

3.  A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods.

Authors:  P Chinna Reddy; K S C Chaitanya; Y Madhusudan Rao
Journal:  Daru       Date:  2011       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.